• RNActive^®
• PUREmessenger^®
• Development Pipeline
• Partnering

OVERVIEW

CureVac has established extensive knowledge and skills with respect to designing and manufacturing potent and stabilized mRNA.

Core Technology Platforms

The following technologies are cornerstones of CureVac's intellectual property:

• RNActive^® for the design of modified mRNA serving a broad range of therapeutic applications,
• RNAdjuvant^® for the use of RNA as an immune stimulant in different kinds of vaccines,
• PUREmessenger^® for the cGMP-production of full-length mRNA.
  
  The combination of these technology platforms enables the Company to develop and manufacture RNA molecules suitable for a broad range of therapeutic applications.